Special Issues
Table of Content

Discover Biomarkers for Personalized Oncology

Submission Deadline: 30 November 2025 (closed) View: 421 Submit to Special Issue

Guest Editors

Prof. William CHO

Email: williamcscho@gmail.com

Affiliation: Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong

Homepage:

Research Interests: utilizing high-throughput technologies to discover biomarkers for cancer diagnosis, treatment prediction and prognostication

图片1.png


Prof. Sanjay Gupta

Email: gxs44@case.edu

Affiliation: Department of Urology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA

Homepage:

Research Interests: cancer biomarkers, cancer therapeutics and drug repurposing and cancer stem cells research


Prof. Dr. Vittorio Gebbia

Email: vittorio.gebbia@gmail.com

Affiliation: Chair of Medical Oncology, School of Medicine, University of Enna Kore, Enna, 94100, ITALY

Homepage:

Research Interests: medial oncology, hematology, lung cancer, chemotherapy


Summary

The rapid advancements in precision medicine have revolutionized cancer diagnosis and treatment, with biomarker discovery playing a pivotal role in personalized oncology. Identifying reliable biomarkers can enhance early detection, predict treatment response, and improve patient outcomes by tailoring therapies to individual genetic and molecular profiles.


This Special Issue aims to explore cutting-edge research on novel biomarkers for various cancer types, including genetic, epigenetic, proteomic, and metabolomic markers. We welcome original research and review articles focusing on biomarker identification, validation, and clinical application in precision oncology. Topics of interest include, but are not limited to:
- Novel diagnostic and prognostic biomarkers
- Biomarkers for predicting therapy response and resistance
- Integration of multi-omics data for biomarker discovery
- AI and machine learning approaches in biomarker research

Through this Special Issue, Oncology Research seeks to advance the development of biomarker-driven strategies that can transform cancer care. We invite researchers to contribute their latest findings to foster innovation in personalized oncology.


Keywords

Biomarkers, Personalized Oncology, Precision Medicine, Cancer Diagnosis, Therapy Response Prediction, Drug Resistance Mechanisms

Published Papers


  • Open Access

    ARTICLE

    PNP as a Metabolic and Prognostic Driver of Breast Cancer Aggressiveness: Insights from Patient Tissue and Cell Models

    Sarra B. Shakartalla, Iman M. Talaat, Nival Ali, Shahenaz S. Salih, Zainab M. Al Shareef, Noura Alkhayyal, Riyad Bendardaf, Sameh S. M. Soliman
    Oncology Research, DOI:10.32604/or.2025.070808
    (This article belongs to the Special Issue: Discover Biomarkers for Personalized Oncology)
    Abstract Objectives: Breast cancer (BC) is the leading cause of cancer-related mortality in women, largely due to metastasis. This study aims to explore the role of purine nucleoside phosphorylase (PNP), a key enzyme in purine metabolism, in the aggressiveness and metastatic behavior of BC. Methods: A comprehensive analysis was performed using in silico transcriptomic data (n = 2509 patients), immunohistochemical profiling of BC tissues (n = 103), and validation through western blotting in multiple BC cell lines. Gene expression and survival analyses were conducted using Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis 2 (GEPIA2), and… More >

  • Open Access

    ARTICLE

    ARPC1B Promotes Clear Cell Renal Cell Carcinoma Progression via the Wnt/β-Catenin Signaling Pathway

    Jiayin Peng, Yijun Xue, Zhiren Cai, Zhaoguan Li, Kangyan Han, Xiaoqi Lin, Yutong Li, Yumin Zhuo
    Oncology Research, Vol.33, No.10, pp. 3127-3154, 2025, DOI:10.32604/or.2025.067340
    (This article belongs to the Special Issue: Discover Biomarkers for Personalized Oncology)
    Abstract Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive malignancy associated with limited treatment options and poor prognosis. Emerging studies suggest that the actin-regulating protein actin-related protein 2/3 complex subunit 1B (ARPC1B), a key regulatory protein within the actin cytoskeleton, could play a pivotal role in ccRCC progression. The current study aimed to uncover the biological functions of ARPC1B and the molecular mechanisms driving its effects in ccRCC. Methods: ARPC1B expression and prognostic implications were analyzed using data sourced from the Gene Expression Profiling Interactive Analysis (GEPIA) platform, immunohistochemical (IHC) staining on 150 tumor… More >

Share Link